《大行報告》瑞銀下調舜宇(02382.HK)目標價至280元 評級「買入」
瑞銀發表告指近日參與了舜宇光學(02382.HK)路演後,指公司管理層對今年增長展望正面,料手機鏡頭升級趨勢將持續,中長期汽車鏡頭增長前景亦正面,並將成主要增長來源。
該行指,舜宇料今年手機鏡頭模組付運可按年增長20%至25%,高於市場預測,並將繼續擴大鏡頭模組業務規模,以改善成本結構。惟均價下降影響毛利率的負面因素或抵銷銷售量增加的正面因素。
瑞銀稱,下調舜宇2021年至2023年盈測1%至2%,目標價相應自285元下調至280元,此按現金流折現率作估值及相當預測未來一年市盈率36倍,維持「買入」評級。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.